Circulating Tumor Cell Diagnostics Market - Global Outlook and Forecast 2022-2028
Circulating tumor cells are significantly useful in determining the status of disease progression rate and projection of therapy needed for tumor eradication. Further development of various tumor markers that can be used along with companion diagnostics to diagnose or monitor various forms of cancer are expected to boost usage rates of CTC tests in the coming years.
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
This report contains market size and forecasts of Circulating Tumor Cell Diagnostics in Global, including the following market information:
Global Circulating Tumor Cell Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Circulating Tumor Cell Diagnostics market was valued at 4980.4 million in 2021 and is projected to reach US$ 8990.7 million by 2028, at a CAGR of 8.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
CTC Enrichment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Circulating Tumor Cell Diagnostics include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc. and Fluxion Biosciences Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Circulating Tumor Cell Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor Cell Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Circulating Tumor Cell Diagnostics Market Segment Percentages, by Type, 2021 (%)
Global Circulating Tumor Cell Diagnostics Market Segment Percentages, by Application, 2021 (%)
Global Circulating Tumor Cell Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Circulating Tumor Cell Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Circulating Tumor Cell Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Circulating tumor cell detection test possesses the ability to detect, quantify, and analyze tumor cells in the blood of cancer patients. It includes enrichment, detection and analysis of the detected circulating tumor cells. Circulating tumor cells tests are applicable in the characterization of tumor cells through biochemical marker analysis. CTC isolation, detection, and molecular characterization systems find investigational application in prostate, breast, colon, head, neck, skin, lung, and pancreatic cancer
Growing incidences oncology diseases and the introduction of novel biotechnological methods that enable the isolation and quantitation of circulating tumor cells. Furthermore, other factors like early disease diagnosis, cost savings on multiple treatments, drug safety, patient compliance, and optimization of therapies are attributive for rising demand for the preventive medicine, thus influencing the demand for CTC tests.
On course of the forecast period it is expected that over 150 companion diagnostic on-label combinations and a range of personalized therapeutic drugs under clinical trials and development pipelines based on companion diagnostics. The level of adoption of companion diagnostics is expected to significantly increase after these obtain complete FDA approval and are commercialized fully.
This report contains market size and forecasts of Circulating Tumor Cell Diagnostics in Global, including the following market information:
Global Circulating Tumor Cell Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Circulating Tumor Cell Diagnostics market was valued at 4980.4 million in 2021 and is projected to reach US$ 8990.7 million by 2028, at a CAGR of 8.8% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
CTC Enrichment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Circulating Tumor Cell Diagnostics include Janssen Diagnostics, Advanced Cell Diagnostics, Aviva Biosciences, Biocept Inc, Biofluidica Inc., CellTraffix Inc., Clearbridge BioMedics Pte Ltd, Epic Sciences Inc. and Fluxion Biosciences Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Circulating Tumor Cell Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Circulating Tumor Cell Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Circulating Tumor Cell Diagnostics Market Segment Percentages, by Type, 2021 (%)
- CTC Enrichment
- CTC Detection
- CTC Analysis
Global Circulating Tumor Cell Diagnostics Market Segment Percentages, by Application, 2021 (%)
- Tumorigenesis research
- EMT biomarkers development
- Cancer stem cell research
- Others
Global Circulating Tumor Cell Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Circulating Tumor Cell Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Circulating Tumor Cell Diagnostics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Janssen Diagnostics
- Advanced Cell Diagnostics
- Aviva Biosciences
- Biocept Inc
- Biofluidica Inc.
- CellTraffix Inc.
- Clearbridge BioMedics Pte Ltd
- Epic Sciences Inc.
- Fluxion Biosciences Inc.
- ScreenCell
- Silicon Biosystems
- Sysmex Corporation
- Greiner Bio-One GmbH
- AdnaGen AG
- Apocell Inc
- Biocep Ltd
- Canopus Bioscience Ltd
- Creatv Microtech Inc
- Ikonisys Inc
- IV Diagnostics Inc
- Miltenyi Biotech GmbH
- Nanostring Technologies Inc
- Rarecells Diagnostics.
- Vitatex Inc
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Circulating Tumor Cell Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Circulating Tumor Cell Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL CIRCULATING TUMOR CELL DIAGNOSTICS OVERALL MARKET SIZE
2.1 Global Circulating Tumor Cell Diagnostics Market Size: 2021 VS 2028
2.2 Global Circulating Tumor Cell Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Circulating Tumor Cell Diagnostics Players in Global Market
3.2 Top Global Circulating Tumor Cell Diagnostics Companies Ranked by Revenue
3.3 Global Circulating Tumor Cell Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Circulating Tumor Cell Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Circulating Tumor Cell Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Tumor Cell Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Circulating Tumor Cell Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Circulating Tumor Cell Diagnostics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Circulating Tumor Cell Diagnostics Market Size Markets, 2021 & 2028
4.1.2 CTC Enrichment
4.1.3 CTC Detection
4.1.4 CTC Analysis
4.2 By Type - Global Circulating Tumor Cell Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Circulating Tumor Cell Diagnostics Revenue, 2017-2022
4.2.2 By Type - Global Circulating Tumor Cell Diagnostics Revenue, 2023-2028
4.2.3 By Type - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Circulating Tumor Cell Diagnostics Market Size, 2021 & 2028
5.1.2 Tumorigenesis research
5.1.3 EMT biomarkers development
5.1.4 Cancer stem cell research
5.1.5 Others
5.2 By Application - Global Circulating Tumor Cell Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Circulating Tumor Cell Diagnostics Revenue, 2017-2022
5.2.2 By Application - Global Circulating Tumor Cell Diagnostics Revenue, 2023-2028
5.2.3 By Application - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Circulating Tumor Cell Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Circulating Tumor Cell Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Circulating Tumor Cell Diagnostics Revenue, 2017-2022
6.2.2 By Region - Global Circulating Tumor Cell Diagnostics Revenue, 2023-2028
6.2.3 By Region - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.3.2 US Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.3.3 Canada Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.3.4 Mexico Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.4.2 Germany Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.3 France Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.4 U.K. Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.5 Italy Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.6 Russia Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.7 Nordic Countries Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.8 Benelux Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.5.2 China Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.3 Japan Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.4 South Korea Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.5 Southeast Asia Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.6 India Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.6.2 Brazil Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.6.3 Argentina Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.7.2 Turkey Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7.3 Israel Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7.4 Saudi Arabia Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7.5 UAE Circulating Tumor Cell Diagnostics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Janssen Diagnostics
7.1.1 Janssen Diagnostics Corporate Summary
7.1.2 Janssen Diagnostics Business Overview
7.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Major Product Offerings
7.1.4 Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.1.5 Janssen Diagnostics Key News
7.2 Advanced Cell Diagnostics
7.2.1 Advanced Cell Diagnostics Corporate Summary
7.2.2 Advanced Cell Diagnostics Business Overview
7.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Major Product Offerings
7.2.4 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.2.5 Advanced Cell Diagnostics Key News
7.3 Aviva Biosciences
7.3.1 Aviva Biosciences Corporate Summary
7.3.2 Aviva Biosciences Business Overview
7.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Major Product Offerings
7.3.4 Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.3.5 Aviva Biosciences Key News
7.4 Biocept Inc
7.4.1 Biocept Inc Corporate Summary
7.4.2 Biocept Inc Business Overview
7.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.4.4 Biocept Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.4.5 Biocept Inc Key News
7.5 Biofluidica Inc.
7.5.1 Biofluidica Inc. Corporate Summary
7.5.2 Biofluidica Inc. Business Overview
7.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.5.4 Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.5.5 Biofluidica Inc. Key News
7.6 CellTraffix Inc.
7.6.1 CellTraffix Inc. Corporate Summary
7.6.2 CellTraffix Inc. Business Overview
7.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.6.4 CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.6.5 CellTraffix Inc. Key News
7.7 Clearbridge BioMedics Pte Ltd
7.7.1 Clearbridge BioMedics Pte Ltd Corporate Summary
7.7.2 Clearbridge BioMedics Pte Ltd Business Overview
7.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Major Product Offerings
7.7.4 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.7.5 Clearbridge BioMedics Pte Ltd Key News
7.8 Epic Sciences Inc.
7.8.1 Epic Sciences Inc. Corporate Summary
7.8.2 Epic Sciences Inc. Business Overview
7.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.8.4 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.8.5 Epic Sciences Inc. Key News
7.9 Fluxion Biosciences Inc.
7.9.1 Fluxion Biosciences Inc. Corporate Summary
7.9.2 Fluxion Biosciences Inc. Business Overview
7.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.9.4 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.9.5 Fluxion Biosciences Inc. Key News
7.10 ScreenCell
7.10.1 ScreenCell Corporate Summary
7.10.2 ScreenCell Business Overview
7.10.3 ScreenCell Circulating Tumor Cell Diagnostics Major Product Offerings
7.10.4 ScreenCell Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.10.5 ScreenCell Key News
7.11 Silicon Biosystems
7.11.1 Silicon Biosystems Corporate Summary
7.11.2 Silicon Biosystems Business Overview
7.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Major Product Offerings
7.11.4 Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.11.5 Silicon Biosystems Key News
7.12 Sysmex Corporation
7.12.1 Sysmex Corporation Corporate Summary
7.12.2 Sysmex Corporation Business Overview
7.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Major Product Offerings
7.12.4 Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.12.5 Sysmex Corporation Key News
7.13 Greiner Bio-One GmbH
7.13.1 Greiner Bio-One GmbH Corporate Summary
7.13.2 Greiner Bio-One GmbH Business Overview
7.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Major Product Offerings
7.13.4 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.13.5 Greiner Bio-One GmbH Key News
7.14 AdnaGen AG
7.14.1 AdnaGen AG Corporate Summary
7.14.2 AdnaGen AG Business Overview
7.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Major Product Offerings
7.14.4 AdnaGen AG Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.14.5 AdnaGen AG Key News
7.15 Apocell Inc
7.15.1 Apocell Inc Corporate Summary
7.15.2 Apocell Inc Business Overview
7.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.15.4 Apocell Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.15.5 Apocell Inc Key News
7.16 Biocep Ltd
7.16.1 Biocep Ltd Corporate Summary
7.16.2 Biocep Ltd Business Overview
7.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Major Product Offerings
7.16.4 Biocep Ltd Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.16.5 Biocep Ltd Key News
7.17 Canopus Bioscience Ltd
7.17.1 Canopus Bioscience Ltd Corporate Summary
7.17.2 Canopus Bioscience Ltd Business Overview
7.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Major Product Offerings
7.17.4 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.17.5 Canopus Bioscience Ltd Key News
7.18 Creatv Microtech Inc
7.18.1 Creatv Microtech Inc Corporate Summary
7.18.2 Creatv Microtech Inc Business Overview
7.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.18.4 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.18.5 Creatv Microtech Inc Key News
7.19 Ikonisys Inc
7.19.1 Ikonisys Inc Corporate Summary
7.19.2 Ikonisys Inc Business Overview
7.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.19.4 Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.19.5 Ikonisys Inc Key News
7.20 IV Diagnostics Inc
7.20.1 IV Diagnostics Inc Corporate Summary
7.20.2 IV Diagnostics Inc Business Overview
7.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.20.4 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.20.5 IV Diagnostics Inc Key News
7.21 Miltenyi Biotech GmbH
7.21.1 Miltenyi Biotech GmbH Corporate Summary
7.21.2 Miltenyi Biotech GmbH Business Overview
7.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Major Product Offerings
7.21.4 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.21.5 Miltenyi Biotech GmbH Key News
7.22 Nanostring Technologies Inc
7.22.1 Nanostring Technologies Inc Corporate Summary
7.22.2 Nanostring Technologies Inc Business Overview
7.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.22.4 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.22.5 Nanostring Technologies Inc Key News
7.23 Rarecells Diagnostics.
7.23.1 Rarecells Diagnostics. Corporate Summary
7.23.2 Rarecells Diagnostics. Business Overview
7.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Major Product Offerings
7.23.4 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.23.5 Rarecells Diagnostics. Key News
7.24 Vitatex Inc
7.24.1 Vitatex Inc Corporate Summary
7.24.2 Vitatex Inc Business Overview
7.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.24.4 Vitatex Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.24.5 Vitatex Inc Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Circulating Tumor Cell Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Circulating Tumor Cell Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL CIRCULATING TUMOR CELL DIAGNOSTICS OVERALL MARKET SIZE
2.1 Global Circulating Tumor Cell Diagnostics Market Size: 2021 VS 2028
2.2 Global Circulating Tumor Cell Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Circulating Tumor Cell Diagnostics Players in Global Market
3.2 Top Global Circulating Tumor Cell Diagnostics Companies Ranked by Revenue
3.3 Global Circulating Tumor Cell Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Circulating Tumor Cell Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Circulating Tumor Cell Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Tumor Cell Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Circulating Tumor Cell Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Circulating Tumor Cell Diagnostics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Circulating Tumor Cell Diagnostics Market Size Markets, 2021 & 2028
4.1.2 CTC Enrichment
4.1.3 CTC Detection
4.1.4 CTC Analysis
4.2 By Type - Global Circulating Tumor Cell Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Circulating Tumor Cell Diagnostics Revenue, 2017-2022
4.2.2 By Type - Global Circulating Tumor Cell Diagnostics Revenue, 2023-2028
4.2.3 By Type - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Circulating Tumor Cell Diagnostics Market Size, 2021 & 2028
5.1.2 Tumorigenesis research
5.1.3 EMT biomarkers development
5.1.4 Cancer stem cell research
5.1.5 Others
5.2 By Application - Global Circulating Tumor Cell Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Circulating Tumor Cell Diagnostics Revenue, 2017-2022
5.2.2 By Application - Global Circulating Tumor Cell Diagnostics Revenue, 2023-2028
5.2.3 By Application - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Circulating Tumor Cell Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Circulating Tumor Cell Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Circulating Tumor Cell Diagnostics Revenue, 2017-2022
6.2.2 By Region - Global Circulating Tumor Cell Diagnostics Revenue, 2023-2028
6.2.3 By Region - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.3.2 US Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.3.3 Canada Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.3.4 Mexico Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.4.2 Germany Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.3 France Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.4 U.K. Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.5 Italy Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.6 Russia Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.7 Nordic Countries Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.4.8 Benelux Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.5.2 China Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.3 Japan Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.4 South Korea Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.5 Southeast Asia Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.5.6 India Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.6.2 Brazil Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.6.3 Argentina Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue, 2017-2028
6.7.2 Turkey Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7.3 Israel Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7.4 Saudi Arabia Circulating Tumor Cell Diagnostics Market Size, 2017-2028
6.7.5 UAE Circulating Tumor Cell Diagnostics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 Janssen Diagnostics
7.1.1 Janssen Diagnostics Corporate Summary
7.1.2 Janssen Diagnostics Business Overview
7.1.3 Janssen Diagnostics Circulating Tumor Cell Diagnostics Major Product Offerings
7.1.4 Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.1.5 Janssen Diagnostics Key News
7.2 Advanced Cell Diagnostics
7.2.1 Advanced Cell Diagnostics Corporate Summary
7.2.2 Advanced Cell Diagnostics Business Overview
7.2.3 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Major Product Offerings
7.2.4 Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.2.5 Advanced Cell Diagnostics Key News
7.3 Aviva Biosciences
7.3.1 Aviva Biosciences Corporate Summary
7.3.2 Aviva Biosciences Business Overview
7.3.3 Aviva Biosciences Circulating Tumor Cell Diagnostics Major Product Offerings
7.3.4 Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.3.5 Aviva Biosciences Key News
7.4 Biocept Inc
7.4.1 Biocept Inc Corporate Summary
7.4.2 Biocept Inc Business Overview
7.4.3 Biocept Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.4.4 Biocept Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.4.5 Biocept Inc Key News
7.5 Biofluidica Inc.
7.5.1 Biofluidica Inc. Corporate Summary
7.5.2 Biofluidica Inc. Business Overview
7.5.3 Biofluidica Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.5.4 Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.5.5 Biofluidica Inc. Key News
7.6 CellTraffix Inc.
7.6.1 CellTraffix Inc. Corporate Summary
7.6.2 CellTraffix Inc. Business Overview
7.6.3 CellTraffix Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.6.4 CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.6.5 CellTraffix Inc. Key News
7.7 Clearbridge BioMedics Pte Ltd
7.7.1 Clearbridge BioMedics Pte Ltd Corporate Summary
7.7.2 Clearbridge BioMedics Pte Ltd Business Overview
7.7.3 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Major Product Offerings
7.7.4 Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.7.5 Clearbridge BioMedics Pte Ltd Key News
7.8 Epic Sciences Inc.
7.8.1 Epic Sciences Inc. Corporate Summary
7.8.2 Epic Sciences Inc. Business Overview
7.8.3 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.8.4 Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.8.5 Epic Sciences Inc. Key News
7.9 Fluxion Biosciences Inc.
7.9.1 Fluxion Biosciences Inc. Corporate Summary
7.9.2 Fluxion Biosciences Inc. Business Overview
7.9.3 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Major Product Offerings
7.9.4 Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.9.5 Fluxion Biosciences Inc. Key News
7.10 ScreenCell
7.10.1 ScreenCell Corporate Summary
7.10.2 ScreenCell Business Overview
7.10.3 ScreenCell Circulating Tumor Cell Diagnostics Major Product Offerings
7.10.4 ScreenCell Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.10.5 ScreenCell Key News
7.11 Silicon Biosystems
7.11.1 Silicon Biosystems Corporate Summary
7.11.2 Silicon Biosystems Business Overview
7.11.3 Silicon Biosystems Circulating Tumor Cell Diagnostics Major Product Offerings
7.11.4 Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.11.5 Silicon Biosystems Key News
7.12 Sysmex Corporation
7.12.1 Sysmex Corporation Corporate Summary
7.12.2 Sysmex Corporation Business Overview
7.12.3 Sysmex Corporation Circulating Tumor Cell Diagnostics Major Product Offerings
7.12.4 Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.12.5 Sysmex Corporation Key News
7.13 Greiner Bio-One GmbH
7.13.1 Greiner Bio-One GmbH Corporate Summary
7.13.2 Greiner Bio-One GmbH Business Overview
7.13.3 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Major Product Offerings
7.13.4 Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.13.5 Greiner Bio-One GmbH Key News
7.14 AdnaGen AG
7.14.1 AdnaGen AG Corporate Summary
7.14.2 AdnaGen AG Business Overview
7.14.3 AdnaGen AG Circulating Tumor Cell Diagnostics Major Product Offerings
7.14.4 AdnaGen AG Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.14.5 AdnaGen AG Key News
7.15 Apocell Inc
7.15.1 Apocell Inc Corporate Summary
7.15.2 Apocell Inc Business Overview
7.15.3 Apocell Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.15.4 Apocell Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.15.5 Apocell Inc Key News
7.16 Biocep Ltd
7.16.1 Biocep Ltd Corporate Summary
7.16.2 Biocep Ltd Business Overview
7.16.3 Biocep Ltd Circulating Tumor Cell Diagnostics Major Product Offerings
7.16.4 Biocep Ltd Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.16.5 Biocep Ltd Key News
7.17 Canopus Bioscience Ltd
7.17.1 Canopus Bioscience Ltd Corporate Summary
7.17.2 Canopus Bioscience Ltd Business Overview
7.17.3 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Major Product Offerings
7.17.4 Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.17.5 Canopus Bioscience Ltd Key News
7.18 Creatv Microtech Inc
7.18.1 Creatv Microtech Inc Corporate Summary
7.18.2 Creatv Microtech Inc Business Overview
7.18.3 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.18.4 Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.18.5 Creatv Microtech Inc Key News
7.19 Ikonisys Inc
7.19.1 Ikonisys Inc Corporate Summary
7.19.2 Ikonisys Inc Business Overview
7.19.3 Ikonisys Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.19.4 Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.19.5 Ikonisys Inc Key News
7.20 IV Diagnostics Inc
7.20.1 IV Diagnostics Inc Corporate Summary
7.20.2 IV Diagnostics Inc Business Overview
7.20.3 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.20.4 IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.20.5 IV Diagnostics Inc Key News
7.21 Miltenyi Biotech GmbH
7.21.1 Miltenyi Biotech GmbH Corporate Summary
7.21.2 Miltenyi Biotech GmbH Business Overview
7.21.3 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Major Product Offerings
7.21.4 Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.21.5 Miltenyi Biotech GmbH Key News
7.22 Nanostring Technologies Inc
7.22.1 Nanostring Technologies Inc Corporate Summary
7.22.2 Nanostring Technologies Inc Business Overview
7.22.3 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.22.4 Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.22.5 Nanostring Technologies Inc Key News
7.23 Rarecells Diagnostics.
7.23.1 Rarecells Diagnostics. Corporate Summary
7.23.2 Rarecells Diagnostics. Business Overview
7.23.3 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Major Product Offerings
7.23.4 Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.23.5 Rarecells Diagnostics. Key News
7.24 Vitatex Inc
7.24.1 Vitatex Inc Corporate Summary
7.24.2 Vitatex Inc Business Overview
7.24.3 Vitatex Inc Circulating Tumor Cell Diagnostics Major Product Offerings
7.24.4 Vitatex Inc Circulating Tumor Cell Diagnostics Revenue in Global Market (2017-2022)
7.24.5 Vitatex Inc Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Circulating Tumor Cell Diagnostics Market Opportunities & Trends in Global Market
Table 2. Circulating Tumor Cell Diagnostics Market Drivers in Global Market
Table 3. Circulating Tumor Cell Diagnostics Market Restraints in Global Market
Table 4. Key Players of Circulating Tumor Cell Diagnostics in Global Market
Table 5. Top Circulating Tumor Cell Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Circulating Tumor Cell Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Circulating Tumor Cell Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Circulating Tumor Cell Diagnostics Product Type
Table 9. List of Global Tier 1 Circulating Tumor Cell Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Circulating Tumor Cell Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Circulating Tumor Cell Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Circulating Tumor Cell Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. Janssen Diagnostics Corporate Summary
Table 31. Janssen Diagnostics Circulating Tumor Cell Diagnostics Product Offerings
Table 32. Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. Advanced Cell Diagnostics Corporate Summary
Table 34. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product Offerings
Table 35. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. Aviva Biosciences Corporate Summary
Table 37. Aviva Biosciences Circulating Tumor Cell Diagnostics Product Offerings
Table 38. Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Biocept Inc Corporate Summary
Table 40. Biocept Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 41. Biocept Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Biofluidica Inc. Corporate Summary
Table 43. Biofluidica Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 44. Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. CellTraffix Inc. Corporate Summary
Table 46. CellTraffix Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 47. CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. Clearbridge BioMedics Pte Ltd Corporate Summary
Table 49. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product Offerings
Table 50. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. Epic Sciences Inc. Corporate Summary
Table 52. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 53. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 54. Fluxion Biosciences Inc. Corporate Summary
Table 55. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 56. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 57. ScreenCell Corporate Summary
Table 58. ScreenCell Circulating Tumor Cell Diagnostics Product Offerings
Table 59. ScreenCell Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 60. Silicon Biosystems Corporate Summary
Table 61. Silicon Biosystems Circulating Tumor Cell Diagnostics Product Offerings
Table 62. Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 63. Sysmex Corporation Corporate Summary
Table 64. Sysmex Corporation Circulating Tumor Cell Diagnostics Product Offerings
Table 65. Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 66. Greiner Bio-One GmbH Corporate Summary
Table 67. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product Offerings
Table 68. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 69. AdnaGen AG Corporate Summary
Table 70. AdnaGen AG Circulating Tumor Cell Diagnostics Product Offerings
Table 71. AdnaGen AG Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 72. Apocell Inc Corporate Summary
Table 73. Apocell Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 74. Apocell Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 75. Biocep Ltd Corporate Summary
Table 76. Biocep Ltd Circulating Tumor Cell Diagnostics Product Offerings
Table 77. Biocep Ltd Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 78. Canopus Bioscience Ltd Corporate Summary
Table 79. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product Offerings
Table 80. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 81. Creatv Microtech Inc Corporate Summary
Table 82. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 83. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 84. Ikonisys Inc Corporate Summary
Table 85. Ikonisys Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 86. Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 87. IV Diagnostics Inc Corporate Summary
Table 88. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 89. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 90. Miltenyi Biotech GmbH Corporate Summary
Table 91. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product Offerings
Table 92. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 93. Nanostring Technologies Inc Corporate Summary
Table 94. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 95. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 96. Rarecells Diagnostics. Corporate Summary
Table 97. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product Offerings
Table 98. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 99. Vitatex Inc Corporate Summary
Table 100. Vitatex Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 101. Vitatex Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 1. Circulating Tumor Cell Diagnostics Market Opportunities & Trends in Global Market
Table 2. Circulating Tumor Cell Diagnostics Market Drivers in Global Market
Table 3. Circulating Tumor Cell Diagnostics Market Restraints in Global Market
Table 4. Key Players of Circulating Tumor Cell Diagnostics in Global Market
Table 5. Top Circulating Tumor Cell Diagnostics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Circulating Tumor Cell Diagnostics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Circulating Tumor Cell Diagnostics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Circulating Tumor Cell Diagnostics Product Type
Table 9. List of Global Tier 1 Circulating Tumor Cell Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Circulating Tumor Cell Diagnostics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Circulating Tumor Cell Diagnostics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Circulating Tumor Cell Diagnostics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Circulating Tumor Cell Diagnostics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2023-2028
Table 30. Janssen Diagnostics Corporate Summary
Table 31. Janssen Diagnostics Circulating Tumor Cell Diagnostics Product Offerings
Table 32. Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 33. Advanced Cell Diagnostics Corporate Summary
Table 34. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Product Offerings
Table 35. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 36. Aviva Biosciences Corporate Summary
Table 37. Aviva Biosciences Circulating Tumor Cell Diagnostics Product Offerings
Table 38. Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 39. Biocept Inc Corporate Summary
Table 40. Biocept Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 41. Biocept Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 42. Biofluidica Inc. Corporate Summary
Table 43. Biofluidica Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 44. Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 45. CellTraffix Inc. Corporate Summary
Table 46. CellTraffix Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 47. CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 48. Clearbridge BioMedics Pte Ltd Corporate Summary
Table 49. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Product Offerings
Table 50. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 51. Epic Sciences Inc. Corporate Summary
Table 52. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 53. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 54. Fluxion Biosciences Inc. Corporate Summary
Table 55. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Product Offerings
Table 56. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 57. ScreenCell Corporate Summary
Table 58. ScreenCell Circulating Tumor Cell Diagnostics Product Offerings
Table 59. ScreenCell Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 60. Silicon Biosystems Corporate Summary
Table 61. Silicon Biosystems Circulating Tumor Cell Diagnostics Product Offerings
Table 62. Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 63. Sysmex Corporation Corporate Summary
Table 64. Sysmex Corporation Circulating Tumor Cell Diagnostics Product Offerings
Table 65. Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 66. Greiner Bio-One GmbH Corporate Summary
Table 67. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Product Offerings
Table 68. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 69. AdnaGen AG Corporate Summary
Table 70. AdnaGen AG Circulating Tumor Cell Diagnostics Product Offerings
Table 71. AdnaGen AG Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 72. Apocell Inc Corporate Summary
Table 73. Apocell Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 74. Apocell Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 75. Biocep Ltd Corporate Summary
Table 76. Biocep Ltd Circulating Tumor Cell Diagnostics Product Offerings
Table 77. Biocep Ltd Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 78. Canopus Bioscience Ltd Corporate Summary
Table 79. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Product Offerings
Table 80. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 81. Creatv Microtech Inc Corporate Summary
Table 82. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 83. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 84. Ikonisys Inc Corporate Summary
Table 85. Ikonisys Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 86. Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 87. IV Diagnostics Inc Corporate Summary
Table 88. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 89. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 90. Miltenyi Biotech GmbH Corporate Summary
Table 91. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Product Offerings
Table 92. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 93. Nanostring Technologies Inc Corporate Summary
Table 94. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 95. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 96. Rarecells Diagnostics. Corporate Summary
Table 97. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Product Offerings
Table 98. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
Table 99. Vitatex Inc Corporate Summary
Table 100. Vitatex Inc Circulating Tumor Cell Diagnostics Product Offerings
Table 101. Vitatex Inc Circulating Tumor Cell Diagnostics Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Circulating Tumor Cell Diagnostics Segment by Type in 2021
Figure 2. Circulating Tumor Cell Diagnostics Segment by Application in 2021
Figure 3. Global Circulating Tumor Cell Diagnostics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Circulating Tumor Cell Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Circulating Tumor Cell Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Circulating Tumor Cell Diagnostics Revenue in 2021
Figure 8. By Type - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Biocept Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. ScreenCell Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. AdnaGen AG Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Apocell Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Biocep Ltd Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 58. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 59. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 60. Vitatex Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Circulating Tumor Cell Diagnostics Segment by Type in 2021
Figure 2. Circulating Tumor Cell Diagnostics Segment by Application in 2021
Figure 3. Global Circulating Tumor Cell Diagnostics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Circulating Tumor Cell Diagnostics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Circulating Tumor Cell Diagnostics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Circulating Tumor Cell Diagnostics Revenue in 2021
Figure 8. By Type - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 12. US Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 16. Germany Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 17. France Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 24. China Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 28. India Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 30. Brazil Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Circulating Tumor Cell Diagnostics Revenue Market Share, 2017-2028
Figure 33. Turkey Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Circulating Tumor Cell Diagnostics Revenue, (US$, Mn), 2017-2028
Figure 37. Janssen Diagnostics Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Advanced Cell Diagnostics Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Aviva Biosciences Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Biocept Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Biofluidica Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. CellTraffix Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Clearbridge BioMedics Pte Ltd Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Epic Sciences Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Fluxion Biosciences Inc. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. ScreenCell Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Silicon Biosystems Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Sysmex Corporation Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Greiner Bio-One GmbH Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. AdnaGen AG Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Apocell Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Biocep Ltd Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Canopus Bioscience Ltd Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Creatv Microtech Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Ikonisys Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. IV Diagnostics Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Miltenyi Biotech GmbH Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 58. Nanostring Technologies Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 59. Rarecells Diagnostics. Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 60. Vitatex Inc Circulating Tumor Cell Diagnostics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
